RBC Capital Downgrades Marinus Pharma to Sector Perform, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams downgraded Marinus Pharma (MRNS) from Outperform to Sector Perform and significantly reduced the price target from $24 to $3, indicating a bearish outlook on the company's stock.
April 17, 2024 | 9:39 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Marinus Pharma was downgraded by RBC Capital from Outperform to Sector Perform, with a price target reduction from $24 to $3, suggesting a negative short-term outlook.
The downgrade by a prominent analyst and the significant reduction in price target are strong indicators of a bearish outlook on Marinus Pharma. This is likely to influence investor sentiment negatively, leading to a potential decrease in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100